Assertio Therapeutics Revenue and Competitors

Location

$42.5M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Assertio Therapeutics's estimated annual revenue is currently $33M per year.(i)
  • Assertio Therapeutics's estimated revenue per employee is $228,917
  • Assertio Therapeutics's total funding is $42.5M.

Employee Data

  • Assertio Therapeutics has 144 Employees.(i)
  • Assertio Therapeutics grew their employee count by 0% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.4M2-67%N/AN/A
#2
$32M1593%N/AN/A
#3
$35M1213%$62.5MN/A
#4
$30.2M15018%N/AN/A
#5
$135.9M676-1%N/AN/A
#6
$14.9M972%$173MN/A
#7
$110.3M549N/AN/AN/A
#8
$62.7M312-3%N/AN/A
#9
$4.9M4932%N/AN/A
#10
$9.2M46-2%N/AN/A
Add Company

Assertio reflects an aspirational mindset that is forward thinking, energetic, and entrepreneurial in spirit. The Assertio mission of advancing patient care is reflected in our three-pillar strategy

keywords:N/A

$42.5M

Total Funding

144

Number of Employees

$33M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Assertio Therapeutics News

2022-04-17 - Global Post herpetic Neuralgia Treatment Market 2022 ...

Pfizer, Arbor Pharma, Assertio Therapeutics, Endo Pharma, Teikoku Pharma, Teva, Mylan, Hengrui Medicine,.

2022-04-17 - Global Post herpetic Neuralgia Treatment Market 2022 ...

Pfizer, Arbor Pharma, Assertio Therapeutics, Endo Pharma, Teikoku Pharma, Teva, Mylan, Hengrui Medicine,.

2022-04-17 - Assertio (NASDAQ:ASRT) Stock Rating Lowered by Zacks ...

The company's business development includes acquisitions, licensing and mergers. Assertio Holdings Inc., formerly known as Assertio Therapeutics...

2022-04-17 - Assertio (NASDAQ:ASRT) Stock Rating Lowered by Zacks ...

The company's business development includes acquisitions, licensing and mergers. Assertio Holdings Inc., formerly known as Assertio Therapeutics...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$32.5M14577%N/A
#2
$23.3M15023%N/A
#3
$44.6M15047%N/A
#4
$24.4M153-1%N/A
#5
$38.5M15422%N/A